Lexaria DehydraTECH Shows Promise in Nervous System Disorders -- CFN Media

SEATTLE, WA, July 05, 2018 (GLOBE NEWSWIRE) -- CFN Media Group (“CFN Media”), the leading agency and financial media network dedicated to the North American cannabis industry, today announced publication of an article covering Lexaria Biosciences Inc. (CSE:LXX) (LXX.CN) (CNSX:LXX) (OTCQX:LXRP), which originally developed its DehydraTECH™ platform to increase the bioavailability of cannabinoids. The company has since broadened its focus well-beyond the cannabis industry. A recent discovery suggests that the proprietary platform may be effective in enabling researchers to deliver APIs past the blood brain barrier. And, investors may want to take note of these developments.

The blood brain barrier is highly effective at protecting the brain from blood-borne pathogens, but it makes it challenging to treat many nervous system disorders. While there are several techniques that researchers have tried, they only work with a small subset of active pharmaceutical ingredients. There is no widely used solution that enables researchers to embed any active ingredient and effectively reach the brain.

Blood Brain Barrier Challenges

The blood brain barrier is designed to protect the brain against circulating toxins in the blood stream. Most charged molecules and molecules over 700 Daltons in size are unable to pass through the barrier, and smaller molecules are often conjugated in the liver. A leaky blood brain barrier is associated with neurological diseases, like epilepsy, brain trauma and edema, and systemic diseases, such as liver failure.

While the blood brain barrier is helpful for protecting the brain, it makes it difficult to treat diseases and disorders of the brain and central nervous system, such as Alzheimer’s disease, Parkinson’s disease, bacterial and viral infections, and cancers of the brain. Many traditional pharmaceuticals try to get around these issues by creating liposome-based carriers, synthesizing polymers, or binding the drug to a carrier -- but each method has its drawbacks.

Researchers continue to seek out innovative new technologies to enable active pharmaceutical ingredients, or APIs, to cross through the blood brain barrier without degrading or becoming less effective. For example, insulin can be transported across the blood brain barrier, but the specificity of the transporter is too high for most pharmacological agents covalently linked to insulin to cross the barrier.

DehydraTECH’s™ Advantages

Lexaria Biosciences recently announced that its DehydraTECH™ drug delivery platform demonstrated enhanced drug delivery to brain tissue. In particular, the company’s in-vivo nicotine animal studies showed that up to 560 percent more nicotine was delivered to brain tissue utilizing DehydraTECH™ compared to concentration-matched controls lacking the DehydraTECH™ enhancements -- which conjugate or join with  APIs for maximum delivery.

The researchers were originally focused on the development of nicotine replacement products. After all, the company could develop oral nicotine products with the same effect as inhaled nicotine, but without the harmful cancer-causing effects of combustion. But, the surprising discovery also suggests that DehydraTECH™ could have a much larger role in treating nervous system disorders by effectively transporting across the blood brain barrier.

After making the discovery, the company filed a new patent application with the USPTO for innovative treatment options for central nervous system diseases and disorders, including ADHD, anxiety, depression, OCD, schizophrenia, Alzheimer’s, Huntington’s, Parkinson’s, neuropathic pain, and more. The company hopes to leverage this patent in the future to develop or outlicense innovative new products using its DehydraTECH™ platform.

Looking Ahead

Lexaria Biosciences Inc. (OTCQX: LXRP) represents a compelling opportunity in the biotech space with its DehydraTECH™ platform. With about 50 patents granted or pending worldwide, the company has made tremendous progress in building its DehydraTECH™ franchise to include the delivery of cannabinoids, terpenes, terpenoids, NSAIDs, vitamins, nicotine, testosterone, and many other drugs.

For more information, visit the company’s website at: https://www.lexariabioscience.com.  

Please follow the link to read the full article: http://www.cannabisfn.com/lexaria-dehydratech-shows-promise-nervous-system-disorders/

About CFN Media

CFN Media (CannabisFN) is the leading agency and financial media network dedicated to the global cannabis industry, helps companies operating in the space attract investors, capital, and publicity. Since 2013, private and public cannabis companies in the US and Canada have relied on CFN Media to grow and succeed.

Learn how to become a CFN Media client company, brand or entrepreneur: http://www.cannabisfn.com/featuredcompany

Download the CFN Media iOS mobile app to access the world of cannabis from the palm of your hand: https://itunes.apple.com/us/app/cannabisfn/id988009247?ls=1&mt=8

Or visit our homepage and enter your mobile number under the Apple App Store logo to receive a download link text on your iPhone: http://www.cannabisfn.com


CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided onhttp://www.cannabisfn.com (the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.  

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/


Contact Data